SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
FRA:SRT3 - Deutsche Boerse Ag - DE0007165631 - Currency: EUR
SRT3 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 15 industry peers in the Life Sciences Tools & Services industry. SRT3 has only an average score on both its financial health and profitability. SRT3 is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRT3 had positive earnings in the past year.
SRT3 had a positive operating cash flow in the past year.
Each year in the past 5 years SRT3 has been profitable.
In the past 5 years SRT3 always reported a positive cash flow from operatings.
1.2 Ratios
SRT3 has a Return On Assets of 0.85%. This is in the lower half of the industry: SRT3 underperforms 76.47% of its industry peers.
SRT3 has a Return On Equity of 3.12%. This is in the lower half of the industry: SRT3 underperforms 70.59% of its industry peers.
With a Return On Invested Capital value of 3.60%, SRT3 is not doing good in the industry: 82.35% of the companies in the same industry are doing better.
Measured over the past 3 years, the Average Return On Invested Capital for SRT3 is significantly above the industry average of 6.82%.
The last Return On Invested Capital (3.60%) for SRT3 is well below the 3 year average (12.95%), which needs to be investigated, but indicates that SRT3 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.85% | ||
| ROE | 3.12% | ||
| ROIC | 3.6% |
ROA(3y)5.81%
ROA(5y)5.51%
ROE(3y)23.1%
ROE(5y)21.8%
ROIC(3y)12.95%
ROIC(5y)12.44%
1.3 Margins
The Profit Margin of SRT3 (2.50%) is worse than 70.59% of its industry peers.
In the last couple of years the Profit Margin of SRT3 has declined.
SRT3's Operating Margin of 12.54% is on the low side compared to the rest of the industry. SRT3 is outperformed by 70.59% of its industry peers.
SRT3's Operating Margin has declined in the last couple of years.
SRT3's Gross Margin of 43.95% is fine compared to the rest of the industry. SRT3 outperforms 64.71% of its industry peers.
In the last couple of years the Gross Margin of SRT3 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.54% | ||
| PM (TTM) | 2.5% | ||
| GM | 43.95% |
OM growth 3Y-9.92%
OM growth 5Y-3.58%
PM growth 3Y-12.42%
PM growth 5Y-7.71%
GM growth 3Y-3.68%
GM growth 5Y-2.1%
2. Health
2.1 Basic Checks
SRT3 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, SRT3 has about the same amount of shares outstanding.
Compared to 5 years ago, SRT3 has about the same amount of shares outstanding.
SRT3 has a worse debt/assets ratio than last year.
2.2 Solvency
SRT3 has an Altman-Z score of 2.38. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
SRT3's Altman-Z score of 2.38 is on the low side compared to the rest of the industry. SRT3 is outperformed by 70.59% of its industry peers.
The Debt to FCF ratio of SRT3 is 9.45, which is on the high side as it means it would take SRT3, 9.45 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.45, SRT3 is doing worse than 76.47% of the companies in the same industry.
A Debt/Equity ratio of 1.66 is on the high side and indicates that SRT3 has dependencies on debt financing.
The Debt to Equity ratio of SRT3 (1.66) is worse than 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.66 | ||
| Debt/FCF | 9.45 | ||
| Altman-Z | 2.38 |
ROIC/WACC0.54
WACC6.69%
2.3 Liquidity
SRT3 has a Current Ratio of 2.02. This indicates that SRT3 is financially healthy and has no problem in meeting its short term obligations.
SRT3 has a Current ratio of 2.02. This is in the better half of the industry: SRT3 outperforms 76.47% of its industry peers.
SRT3 has a Quick Ratio of 1.13. This is a normal value and indicates that SRT3 is financially healthy and should not expect problems in meeting its short term obligations.
SRT3's Quick ratio of 1.13 is fine compared to the rest of the industry. SRT3 outperforms 64.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.13 |
3. Growth
3.1 Past
The earnings per share for SRT3 have decreased strongly by -48.38% in the last year.
SRT3 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.05% yearly.
The Revenue for SRT3 has decreased by -18.66% in the past year. This is quite bad
Measured over the past years, SRT3 shows a quite strong growth in Revenue. The Revenue has been growing by 16.74% on average per year.
EPS 1Y (TTM)-48.38%
EPS 3Y4.09%
EPS 5Y14.05%
EPS Q2Q%-8.42%
Revenue 1Y (TTM)-18.66%
Revenue growth 3Y13.29%
Revenue growth 5Y16.74%
Sales Q2Q%-6.61%
3.2 Future
The Earnings Per Share is expected to grow by 12.96% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.23% on average over the next years.
EPS Next Y-17.05%
EPS Next 2Y1.9%
EPS Next 3Y9.64%
EPS Next 5Y12.96%
Revenue Next Year-1.28%
Revenue Next 2Y3.1%
Revenue Next 3Y5.47%
Revenue Next 5Y7.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 46.36, SRT3 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, SRT3 is valued a bit more expensive than the industry average as 70.59% of the companies are valued more cheaply.
SRT3's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.35.
With a Price/Forward Earnings ratio of 44.64, SRT3 can be considered very expensive at the moment.
82.35% of the companies in the same industry are cheaper than SRT3, based on the Price/Forward Earnings ratio.
SRT3's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.36 | ||
| Fwd PE | 44.64 |
4.2 Price Multiples
70.59% of the companies in the same industry are cheaper than SRT3, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SRT3 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.8 | ||
| EV/EBITDA | 26.21 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.3
EPS Next 2Y1.9%
EPS Next 3Y9.64%
5. Dividend
5.1 Amount
With a yearly dividend of 0.38%, SRT3 is not a good candidate for dividend investing.
SRT3's Dividend Yield is comparable with the industry average which is at 0.79.
With a Dividend Yield of 0.38, SRT3 pays less dividend than the S&P500 average, which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
5.2 History
The dividend of SRT3 is nicely growing with an annual growth rate of 23.23%!
Dividend Growth(5Y)23.23%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
SRT3 pays out 60.94% of its income as dividend. This is not a sustainable payout ratio.
The dividend of SRT3 is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP60.94%
EPS Next 2Y1.9%
EPS Next 3Y9.64%
FRA:SRT3 (3/7/2025, 5:36:15 PM)
229
-11.5 (-4.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners2.79%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap17.15B
Analysts77.14
Price Target376.37 (64.35%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
Yearly Dividend1.44
Dividend Growth(5Y)23.23%
DP60.94%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.25%
Min EPS beat(2)1.69%
Max EPS beat(2)26.82%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.7%
Min Revenue beat(2)-4.07%
Max Revenue beat(2)2.67%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.84%
PT rev (3m)4.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.13%
EPS NY rev (1m)-3.1%
EPS NY rev (3m)-0.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.85%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.36 | ||
| Fwd PE | 44.64 | ||
| P/S | 5.16 | ||
| P/FCF | 35.8 | ||
| P/OCF | 18.56 | ||
| P/B | 6.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 26.21 |
EPS(TTM)4.94
EY2.16%
EPS(NY)5.13
Fwd EY2.24%
FCF(TTM)6.4
FCFY2.79%
OCF(TTM)12.34
OCFY5.39%
SpS44.39
BVpS35.64
TBVpS-36.89
PEG (NY)N/A
PEG (5Y)3.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.85% | ||
| ROE | 3.12% | ||
| ROCE | 4.73% | ||
| ROIC | 3.6% | ||
| ROICexc | 3.87% | ||
| ROICexgc | 11.44% | ||
| OM | 12.54% | ||
| PM (TTM) | 2.5% | ||
| GM | 43.95% | ||
| FCFM | 14.41% |
ROA(3y)5.81%
ROA(5y)5.51%
ROE(3y)23.1%
ROE(5y)21.8%
ROIC(3y)12.95%
ROIC(5y)12.44%
ROICexc(3y)13.8%
ROICexc(5y)13.16%
ROICexgc(3y)37.98%
ROICexgc(5y)34.91%
ROCE(3y)16.99%
ROCE(5y)16.32%
ROICexcg growth 3Y-20.65%
ROICexcg growth 5Y-7.88%
ROICexc growth 3Y-23.31%
ROICexc growth 5Y-14.87%
OM growth 3Y-9.92%
OM growth 5Y-3.58%
PM growth 3Y-12.42%
PM growth 5Y-7.71%
GM growth 3Y-3.68%
GM growth 5Y-2.1%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.66 | ||
| Debt/FCF | 9.45 | ||
| Debt/EBITDA | 5.52 | ||
| Cap/Depr | 115.38% | ||
| Cap/Sales | 13.39% | ||
| Interest Coverage | 2.1 | ||
| Cash Conversion | 115.16% | ||
| Profit Quality | 575.72% | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.13 | ||
| Altman-Z | 2.38 |
F-Score5
WACC6.69%
ROIC/WACC0.54
Cap/Depr(3y)173.89%
Cap/Depr(5y)164.93%
Cap/Sales(3y)13.6%
Cap/Sales(5y)12.69%
Profit Quality(3y)106.12%
Profit Quality(5y)109.16%
High Growth Momentum
Growth
EPS 1Y (TTM)-48.38%
EPS 3Y4.09%
EPS 5Y14.05%
EPS Q2Q%-8.42%
EPS Next Y-17.05%
EPS Next 2Y1.9%
EPS Next 3Y9.64%
EPS Next 5Y12.96%
Revenue 1Y (TTM)-18.66%
Revenue growth 3Y13.29%
Revenue growth 5Y16.74%
Sales Q2Q%-6.61%
Revenue Next Year-1.28%
Revenue Next 2Y3.1%
Revenue Next 3Y5.47%
Revenue Next 5Y7.23%
EBIT growth 1Y-36.46%
EBIT growth 3Y2.04%
EBIT growth 5Y12.57%
EBIT Next Year45.5%
EBIT Next 3Y25.3%
EBIT Next 5Y19.89%
FCF growth 1Y191.92%
FCF growth 3Y2.71%
FCF growth 5Y91.74%
OCF growth 1Y35.92%
OCF growth 3Y18.61%
OCF growth 5Y28.41%